AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36464218 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 116
Study 36464242 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofilament suture
Number of subjects: 0
Study 36464242 — intervention group
Group type: COMPARATOR
Intervention: Multifilament suture
Number of subjects: 0
Study 36464584 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome interactions with cancer immunotherapy
Number of subjects: 0
Study 36464584 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical efforts to utilize microbiome knowledge
Number of subjects: 0
Study 36464714 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-automated vitrification
Number of subjects: 0
Study 36464714 — intervention group
Group type: COMPARATOR
Intervention: Manual vitrification
Number of subjects: 0
Study 36464714 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 0
Study 36464714 — intervention group
Group type: COMPARATOR
Intervention: Fresh oocytes
Number of subjects: 0
Study 36464928 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD symptoms measured using the PTSD Checklist for DSM-5 (PCL-5)
Number of subjects: 254
Study 36465342 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 381
Study 36465342 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 4 lymphopenia during CCRT (3 weeks)
Number of subjects: 381
Study 36465342 — intervention group
Group type: EXPERIMENTAL
Intervention: G1-4 lymphopenia 2 months after CCRT
Number of subjects: 381
Study 36465342 — intervention group
Group type: EXPERIMENTAL
Intervention: G1-4 lymphopenia 6 months after CCRT (6m-post-CCRT)
Number of subjects: 381
Study 36465342 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC nadir
Number of subjects: 381
Study 36465342 — intervention group
Group type: EXPERIMENTAL
Intervention: 6m-post-CCRT G1-4 lymphopenia
Number of subjects: 381
Study 36465342 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation dose
Number of subjects: 381
Study 36465342 — intervention group
Group type: EXPERIMENTAL
Intervention: GTV volume
Number of subjects: 381
Study 36465342 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline TLC
Number of subjects: 381
Study 36465445 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum level of calpains
Number of subjects: 70
Study 36465445 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum level of calpains
Number of subjects: 70
Study 36465469 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular intervention for tibial runoff
Number of subjects: 1200
Study 36465469 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention for tibial runoff
Number of subjects: 1200
Study 36465905 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Radium-223
Number of subjects: 0
Study 36465920 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop oxygen control for 2 hours
Number of subjects: 23
Study 36465920 — intervention group
Group type: COMPARATOR
Intervention: Manual oxygen titrations for 2 hours
Number of subjects: 23
Study 36466215 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Awareness and Expression Therapy (EAET) class
Number of subjects: 74
Study 36466423 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term fasting (LF) for 9 ± 3 days (250 kcal/day)
Number of subjects: 100
Study 36466423 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term fasting (LF) for 12 days
Number of subjects: 100
Study 36466423 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after fasting
Number of subjects: 100
Study 36466746 — intervention group
Group type: COMPARATOR
Intervention: VMATc (2 coplanar arcs)
Number of subjects: 10
Study 36466746 — intervention group
Group type: EXPERIMENTAL
Intervention: VMATc + nc (coplanar and 3 non-coplanar arcs)
Number of subjects: 10
Study 36467036 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine plasma concentrations sustained at 2-3 ng/ml
Number of subjects: 543
Study 36467036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 543
Study 36467262 — intervention group
Group type: EXPERIMENTAL
Intervention: Active bilateral vagal stimulation (45 min duration with 30s alternative episodes of active/rest periods; 3mA; 200-300μs current width, 25Hz)
Number of subjects: 44
Study 36467262 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 44
Study 36467287 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical care bundle for early detection and first-response PPH management
Number of subjects: 45
Study 36467287 — intervention group
Group type: EXPERIMENTAL
Intervention: In-service training on emergency obstetric care
Number of subjects: 45
Study 36467287 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective measurement of blood loss
Number of subjects: 45
Study 36467452 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 100 mg QD to 400 mg QD
Number of subjects: 20
Study 36467452 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib treatment
Number of subjects: 20
Study 36467815 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor de-escalation or discontinuation
Number of subjects: 0
Study 36468466 — intervention group
Group type: EXPERIMENTAL
Intervention: SIII-GC-PD
Number of subjects: 72
Study 36468499 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated SMS (n = 132)
Number of subjects: 752
Study 36468499 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated and tailored SMS + Peer Navigation (SMS + PN) (n = 133)
Number of subjects: 752
Study 36468499 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS + PN
Number of subjects: 752
Study 36468499 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) (n = 87)
Number of subjects: 752
Study 36468635 — intervention group
Group type: EXPERIMENTAL
Intervention: BMAC intra-articular injection combined with subchondral BMAC injection
Number of subjects: 86
Study 36468635 — intervention group
Group type: COMPARATOR
Intervention: BMAC intra-articular injection alone
Number of subjects: 86
Study 36469077 — intervention group
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA PET/CT
Number of subjects: 1
Study 36469077 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-fluciclovine PET/CT
Number of subjects: 1
Study 36469077 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Number of subjects: 1
Study 36469095 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplant CD45RA-depleted donor lymphocyte infusions (DLI)
Number of subjects: 19
Study 36469103 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital measures from smartphone-based tests (Floodlight Proof-of-Concept app) including Draw a Shape Test and Pinching Test.
Number of subjects: 62
Study 36469103 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard clinical measures (e.g., Nine-Hole Peg Test [9HPT]).
Number of subjects: 62
Study 36469250 — intervention group
Group type: EXPERIMENTAL
Intervention: Kollidon VA64®-based eliapixant formulation (400 mg; fasted)
Number of subjects: 30
Study 36469250 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release eliapixant
Number of subjects: 30
Study 36469250 — intervention group
Group type: EXPERIMENTAL
Intervention: Two amorphous solid dispersion (ASD) formulations
Number of subjects: 30
Study 36469250 — intervention group
Group type: COMPARATOR
Intervention: Suspension-based formulation
Number of subjects: 30
Study 36469289 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (Nutritious Eating with Soul study)
Number of subjects: 150
Study 36469321 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacritinib (400 mg on day 1 followed by 200 mg twice daily on days 2-14)
Number of subjects: 200
Study 36469321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 36469321 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacritinib
Number of subjects: 200
Study 36469400 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced PrEP implementation strategy in STI clinic
Number of subjects: 0
Study 36469400 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted partner notification
Number of subjects: 0
Study 36469400 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP users
Number of subjects: 0
Study 36469400 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic staff participants
Number of subjects: 0
Study 36469726 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy initiated at age 2 to <4 years
Number of subjects: 3318
Study 36469726 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy initiated at age 4 to <6 years
Number of subjects: 3318
Study 36469726 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy initiated at age ≥6 years
Number of subjects: 3318
Study 36469736 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue insulin sensitivity/resistance evaluated using OGTT-derived surrogates
Number of subjects: 213
Study 36469736 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body insulin sensitivity
Number of subjects: 213
Study 36469736 — intervention group
Group type: EXPERIMENTAL
Intervention: Low postprandial free fatty acid concentrations
Number of subjects: 213
Study 36469736 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in body mass index (BMI) z score
Number of subjects: 213
Study 36469840 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib monotherapy
Number of subjects: 30
Study 36469840 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib monotherapy in patients with epithelial ovarian cancer
Number of subjects: 30
Study 36469915 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based care with a clinical decision support system (CDSS)
Number of subjects: 11132
Study 36469915 — intervention group
Group type: COMPARATOR
Intervention: Team-based care alone
Number of subjects: 11132
Study 36469995 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-sample capture-recapture analysis using four statewide datasets (Registry of Vital Statistics, EMS, PDMP, Kentucky Medicaid)
Number of subjects: 1000
Study 36470149 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 100/62.5/25 μg
Number of subjects: 10355
Study 36470149 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroid-containing therapy
Number of subjects: 10355
Study 36470291 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine-tipiracil plus bevacizumab
Number of subjects: 856
Study 36470291 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine plus bevacizumab
Number of subjects: 856
Study 36470418 — intervention group
Group type: EXPERIMENTAL
Intervention: PPAH risk model
Number of subjects: 247
Study 36470418 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted drugs
Number of subjects: 247
Study 36470464 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanostomy tube placement
Number of subjects: 100
Study 36470464 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 100
Study 36470507 — intervention group
Group type: EXPERIMENTAL
Intervention: Indeterminate diastolic function
Number of subjects: 330
Study 36470507 — intervention group
Group type: COMPARATOR
Intervention: No diastolic dysfunction
Number of subjects: 330
Study 36470507 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite diastolic dysfunction
Number of subjects: 330
Study 36470546 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2-I users
Number of subjects: 646
Study 36470546 — intervention group
Group type: COMPARATOR
Intervention: non-SGLT2-I users
Number of subjects: 646
Study 36470745 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-opioid analgesics (NSAID, paracetamol, metamizole)
Number of subjects: 898
Study 36470745 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 898
Study 36470745 — intervention group
Group type: COMPARATOR
Intervention: Non-opioid analgesics
Number of subjects: 898
Study 36470745 — intervention group
Group type: COMPARATOR
Intervention: Non-opioid analgesics before end of surgery
Number of subjects: 898
Study 36470745 — intervention group
Group type: COMPARATOR
Intervention: Opioid doses
Number of subjects: 898
Study 36470974 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC-1 at 750 mg/day
Number of subjects: 48
Study 36470974 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC-1
Number of subjects: 48
Study 36471036 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 0
Study 36471036 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36471059 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon capsule endoscopy (CCE) as an alternative to CT colonography
Number of subjects: 65
Study 36471059 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon capsule endoscopy (CCE) as an alternative to AA colonoscopy
Number of subjects: 65
Study 36471142 — intervention group
Group type: EXPERIMENTAL
Intervention: Protamine administration at a rate of 25 mg·min
Number of subjects: 28
Study 36471142 — intervention group
Group type: EXPERIMENTAL
Intervention: Protamine:heparin ratio of 0.3
Number of subjects: 28
Study 36471142 — intervention group
Group type: EXPERIMENTAL
Intervention: Protamine:heparin ratio of 0.5
Number of subjects: 28
Study 36471142 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-CPB activated clotting time
Number of subjects: 28
Study 36471184 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational thromboelastometry analysis at T0 and T1
Number of subjects: 68
Study 36471184 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen levels on postoperative day 1 (T1)
Number of subjects: 68
Study 36471184 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 68
Study 36471184 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of hypocoagulation
Number of subjects: 68
Study 36471222 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 300-mg oral dose of tucatinib
Number of subjects: 0
Study 36471222 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 0
Study 36471253 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 8% (Qutenza®) patch applied at three time intervals
Number of subjects: 130
Study 36471392 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition of care model
Number of subjects: 0
Study 36471891 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-informed yoga intervention (6-week, twice-weekly sessions)
Number of subjects: 0
Study 36471891 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36472134 — intervention group
Group type: EXPERIMENTAL
Intervention: lemborexant 5 mg
Number of subjects: 0
Study 36472134 — intervention group
Group type: EXPERIMENTAL
Intervention: lemborexant 10 mg
Number of subjects: 0
Study 36472134 — intervention group
Group type: EXPERIMENTAL
Intervention: zolpidem tartrate extended-release 6.25 mg
Number of subjects: 0
Study 36472134 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 36472162 — intervention group
Group type: COMPARATOR
Intervention: Medium-dose triple therapy
Number of subjects: 17161
Study 36472162 — intervention group
Group type: COMPARATOR
Intervention: High-dose triple therapy
Number of subjects: 17161
Study 36472162 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 17161
Study 36472162 — intervention group
Group type: COMPARATOR
Intervention: High-dose ICS/LABA
Number of subjects: 17161
Study 36472189 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Failure (HF)
Number of subjects: 2981
Study 36472189 — intervention group
Group type: COMPARATOR
Intervention: Community without HF
Number of subjects: 2981
Study 36472300 — intervention group
Group type: EXPERIMENTAL
Intervention: High-specific-activity I-131 meta-iodobenzylguanidine (dose: ~18.5 GBq (~500 mCi))
Number of subjects: 68
Study 36472416 — intervention group
Group type: COMPARATOR
Intervention: Educational interventions
Number of subjects: 21149
Study 36472416 — intervention group
Group type: COMPARATOR
Intervention: Self-management interventions
Number of subjects: 21149
Study 36472416 — intervention group
Group type: COMPARATOR
Intervention: Educational with self-management interventions
Number of subjects: 21149
Study 36472536 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model using diffusion-weighted imaging (DWI) and clinical information to predict hypoperfusion lesion and identify target mismatch profile.
Number of subjects: 0
Study 36472536 — intervention group
Group type: COMPARATOR
Intervention: Perfusion MRI as the reference standard for comparison.
Number of subjects: 0
Study 36472579 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 3.0 mg/day
Number of subjects: 195
Study 36472579 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 195
Study 36472579 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise treatment
Number of subjects: 195
Study 36472579 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide treatment
Number of subjects: 195
Study 36472719 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC) treatment including direct oral anticoagulants (DOAC) and vitamin K antagonists (VKA)
Number of subjects: 958
Study 36472719 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-anaemic patients)
Number of subjects: 958
Study 36472719 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC therapy in anaemic patients
Number of subjects: 958
Study 36472728 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix (loading dose 360 mg at Day -14, then 120 mg/day until Day -1; followed by 120 mg/day with apalutamide 240 mg from Day 1 to Day 28)
Number of subjects: 12
Study 36472728 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix + Apalutamide (120 mg/day of relugolix with 240 mg of apalutamide from Day 1 to Day 28)
Number of subjects: 12
Study 36472728 — intervention group
Group type: COMPARATOR
Intervention: Relugolix monotherapy
Number of subjects: 12
Study 36472728 — intervention group
Group type: COMPARATOR
Intervention: Relugolix + Apalutamide
Number of subjects: 12
Study 36472802 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-fraction Motion Review (IMR)
Number of subjects: 0
Study 36472802 — intervention group
Group type: COMPARATOR
Intervention: Kilovoltage Intra-fraction Motion management (KIM)
Number of subjects: 0
Study 36472802 — intervention group
Group type: COMPARATOR
Intervention: MV/kV triangulation
Number of subjects: 0
Study 36472876 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaboration on common errors in patient treatment combined with individualized mailed feedback
Number of subjects: 0
Study 36472876 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36472884 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 3398
Study 36472904 — intervention group
Group type: EXPERIMENTAL
Intervention: Call for Life Uganda (CFLU) interactive voice response tool providing daily pill reminders, preappointment reminders, symptom reporting, and health promotion tips.
Number of subjects: 0
Study 36472904 — intervention group
Group type: EXPERIMENTAL
Intervention: Call for Life Uganda (CFLU) interactive voice response tool.
Number of subjects: 0
Study 36472992 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition identified using GLIM criteria
Number of subjects: 381000
Study 36472992 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty assessed using the accumulation of deficits model
Number of subjects: 381000
Study 36472992 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty assessed using the phenotype model
Number of subjects: 381000
Study 36472992 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia assessed according to EWGSOP standards
Number of subjects: 381000
Study 36473106 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib + methotrexate (MTX)
Number of subjects: 0
Study 36473106 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab + methotrexate (MTX)
Number of subjects: 0
Study 36473106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36473121 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg loading dose followed by 0.5 mg/day until discharge) plus atorvastatin 80 mg
Number of subjects: 0
Study 36473121 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 80 mg
Number of subjects: 0
Study 36473121 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine plus atorvastatin
Number of subjects: 0
Study 36473126 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment and management (GAM) for 6 months
Number of subjects: 350
Study 36473126 — intervention group
Group type: COMPARATOR
Intervention: Usual oncologic care (control)
Number of subjects: 350
Study 36473143 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 947
Study 36473143 — intervention group
Group type: COMPARATOR
Intervention: EXTREME regimen (cetuximab plus cisplatin/carboplatin plus fluorouracil ≤ six cycles, then cetuximab maintenance)
Number of subjects: 947
Study 36473143 — intervention group
Group type: COMPARATOR
Intervention: EXTREME regimen
Number of subjects: 947
Study 36473164 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary factors assessment
Number of subjects: 0
Study 36473172 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-the-shelf exergame intervention
Number of subjects: 0
Study 36473172 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36473198 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia at 33°C ± 1°C
Number of subjects: 82
Study 36473198 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 82
Study 36473400 — intervention group
Group type: EXPERIMENTAL
Intervention: NOACs
Number of subjects: 0
Study 36473400 — intervention group
Group type: COMPARATOR
Intervention: Control (before NOACs entered medical insurance)
Number of subjects: 0
Study 36473633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab treatment
Number of subjects: 0
Study 36473633 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36473808 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES+HPRO+PT
Number of subjects: 39
Study 36473808 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 39